As the 2024 ASRS meeting draws nearer, more companies announce the presentations related to their research. The annual event will take place in Stockholm, Sweden, July 17-20, 2024. Read more: https://lnkd.in/eXQ44Qwa
Modern Retina
Media Production
Cleveland, Ohio 3,009 followers
Information on technology and clinical practice essential to your community.
About us
The leading source for retina. We cover AMD, DME, diabetic retinopathy, uveitis, and more. Affiliated with Ophthalmology Times.
- Website
-
http://www.modernretina.com
External link for Modern Retina
- Industry
- Media Production
- Company size
- 501-1,000 employees
- Headquarters
- Cleveland, Ohio
- Founded
- 2017
Updates
-
A review shows sozinibercept’s potential to prevent blood vessel growth and vascular leakage in the retina as a treatment for wet AMD. The recognition is that the “pathophysiology is broader than dysregulation or overproduction of VEGF-A. Read more: https://lnkd.in/ePDJWUcB
Approach to wet AMD treatment explores VEGF-C and VEGF-D pathways
modernretina.com
-
Boston researchers reported that there is a potential risk of the development of non-arteritic ischemic optic neuropathy (NAION) associated with prescriptions for semaglutide (Wegovy, Ozempic, Novo Nordisk). Read more: https://lnkd.in/eV5jS_uV
Study suggests potential link between semaglutide and risk of non-arteritic ischemic optic neuropathy
modernretina.com
-
A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD. Read more: https://lnkd.in/eDRXzQBg
Study zeroes in on new target for treatment of one type of macular degeneration
modernretina.com
-
Genentech, a member of the Roche group, has received FDA approval to relaunch Susvimo (ranibizumab injection 100 mg/mL) for intravitreal use via an ocular implant for treating people with wet (or neovascular) age-related macular degeneration (AMD). Read more: https://lnkd.in/eHVbvwD4
Genentech receives FDA approval to relaunch Susvimo
modernretina.com
-
The 42nd annual meeting of the American Society of Retina Specialists (ASRS) is slated to convene in the northern European capital city of Stockholm from July 17-20, 2024. The venue is the Stockholmsmässan Convention Center, Stockholm. Read more: https://lnkd.in/eBhswn5i
ASRS: Premier meeting for retina science and innovation
modernretina.com
-
Genentech this week announced the FDA has approved faricimab-svoa (Vabysmo) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Read more: https://lnkd.in/euFJ2war
FDA approves faricimab-svoa prefilled syringe
modernretina.com
-
The European Medicines Agency (EMA) issued a new opinion from its Committee for Medicinal Products for Human Use (CHMP), regarding faricimab (Vabysmo). Read more: https://lnkd.in/ex423XWc
EMA issues positive CHMP opinion for faricimab in third indication RVO
modernretina.com
-
Altos Biologics Inc. has submitted the Marketing Authorization Application to the European Medicines Agency (EMA) for ALT-L9, an aflibercept biosimilar. This biosimilar was developed by Alteogen. Altos Biologics Inc. is a subsidiary of Alteogen. Read more: https://lnkd.in/eXtTM_uj
Altos Biologics submits Marketing Authorization Application to the EMA for ALT-L9, an aflibercept biosimilar
modernretina.com
-
During interview earlier this year, we asked leaders in the retina field would tell residents and medical students as they train for the next decades in retinal care. Here's what Durga Borkar, MD, MMCi, and Jaclyn L. Kovach, MD, had to say. Watch now: https://lnkd.in/euSpfrGu
Geographic atrophy and future plans: What residents should consider
modernretina.com